| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
A total of 36 patients with rheumatoid arthritis (RA) who had been in sustained remission for at least 6 months with biologic disease-modifying anti rheumatic drug (bDMARD) and preferred to discontinue bDMARD were enrolled in this study. Twenty patients developed RA flare and almost all of them returned to remission state with the re-introduction of the same bDMARD. It was difficult to predict the RA flare after bDMARD discontinuation. However, this study demonstrates that patient symptom is a sensitive measure of disease flare, blood concentration of cytokines and their receptors varies among patients receiving different bDMARDs, and interleukin-6 is the best biomarker of RA activity.
|
